共 118 条
[1]
Jankovic J(2020)Parkinson’s disease: etiopathogenesis and treatment J Neurol Neurosurg Psychiatry 91 795-808
[2]
Tan EK(2022)Therapeutics in the pipeline targeting alpha-synuclein for parkinson’s disease Pharmacol Rev 74 207-37
[3]
Grosso Jasutkar H(2020)Parkinson disease and the immune system - associations, mechanisms and therapeutics Nat Rev Neurol 16 303-18
[4]
Oh SE(2012)Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission J Neurosci 32 13454-69
[5]
Mouradian MM(2022)Trial of cinpanemab in early parkinson’s disease N Engl J Med 387 408-20
[6]
Tan EK(2014)Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in parkinson’s disease-like models J Neurosci 34 9441-54
[7]
Chao YX(2022)Trial of prasinezumab in early-stage parkinson’s disease N Engl J Med 387 421-32
[8]
West A(2019)Development of an aggregate-selective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in parkinson’s disease models Neurobiol Dis 124 276-88
[9]
Chan LL(2019)Randomized phase I clinical trial of anti-alpha-synuclein antibody BIIB054 Mov Disord 34 1154-63
[10]
Poewe W(2018)Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with parkinson disease: a randomized clinical trial JAMA Neurol 75 1206-14